This award provides an additional $3.65 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), on top of the $2.08 million in funding that Siga has already received from this grant.
Eric Rose, CEO of Siga, said: “The additional funding received from NIAID affords us the ability to continue to explore the possibilities of ST-193 as a commercialized antiviral for Lassa fever. We believe this is a much needed drug given the severity of the disease and the large number of individuals it affects each year.”